Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.54 |
| ▸ | HSP90B1 | P14625 | 4/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21710750 | 0.91 | ADORA3 (0.52) | ADORA3HSP90B1HSP90AA1ADORA2AADORA1 | |
| SCHEMBL26934922 | 0.84 | P2RY1 (0.44) | ADORA3HSP90B1HSP90AA1ADORA2AADORA1 | |
| SCHEMBL22933030 | 0.84 | P2RY1 (0.44) | ADORA3HSP90B1HSP90AA1ADORA2AADORA1 | |
| SCHEMBL19807380 | 0.84 | ADORA3 (0.56) | ADORA3ADORA2AADORA1TMIGD3HTR2C | |
| SCHEMBL22937442 | 0.84 | P2RY1 (0.44) | ADORA3HSP90B1HSP90AA1ADORA2AADORA1 | |
| SCHEMBL22937475 | 0.80 | ADORA3 (0.50) | ADORA3HSP90B1HSP90AA1ADORA2AADORA1 | |
| SCHEMBL19503946 | 0.77 | ADORA3 (0.55) | ADORA3HSP90B1HSP90AA1ADORA2AADORA1 | |
| SCHEMBL21710772 | 0.76 | P2RY1 (0.42) | ADORA3HSP90B1HSP90AA1ADORA1LMNA | |
| SCHEMBL21710891 | 0.76 | P2RY1 (0.42) | ADORA3HSP90B1HSP90AA1ADORA1LMNA | |
| SCHEMBL21710871 | 0.75 | ADORA3 (0.64) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | ASTROCYTE PHARMACEUTICALS, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885HSP90B1 1135/4885HSP90AA1 1092/4885 |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885HSP90B1 1135/4885HSP90AA1 1092/4885 |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | SLC6A3, PNMT, CES2 | ADORA3 274/4885HSP90B1 3289/4885HSP90AA1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.